Pioneering The Development of Novel Precision Oncology Drugs Targeting Stress Support Pathways

Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.

Learn More

Our Proprietary BEACON+ Platform

We have created our proprietary BEACON+ platform to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop small molecules for the treatment of cancer.

Learn More

RBN-2397 – PARP7 Inhibitor

Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.

Learn More
June 4

Cambridge, MA

Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting

Learn More
Join our team of experts.
Find Out More